Trial Profile
Retrospective study of lyso-Gb3 plasma concentration in Fabry patients receiving ERT/Replagal
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Oct 2016
Price :
$35
*
At a glance
- Drugs Agalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Pharmacodynamics
- 04 Oct 2016 Status changed from recruiting to completed.
- 01 Dec 2015 New trial record